GILD Stock Surging on Coronavirus Treatment Reports

Some experts say there's still more to be done before efficacy is confirmed

Assistant Editor
Apr 17, 2020 at 10:07 AM
facebook twitter linkedin

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) are surging, last seen up 10.6%, at $84.66, after an encouraging report suggested the biotech company’s antiviral medication remdesivir may be effective at treating patients with severe cases of COVID-19. Conversely, there is some pessimism surrounding these findings, with Baird in particular saying that despite painting a pretty picture, the report lacks critical analysis. 

On the charts, GILD is continuing to benefit from the long-term support of its rising, 40-day moving average. Today’s rise fuels optimism surrounding the stock, as GILD boasts a 29% year-to-date gain.

Despite this, analysts are still split on the security. Of the 20 in coverage, sentiment is evenly divided. Half call it a “buy” or better, and the remaining sport a “hold” or worse. Meanwhile, the consensus 12-month price target of $75.32 is a 10% discount to current levels.

In the options pits, calls reign supreme. GILD sports a 50-day call/put volume ratio of 5.33 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio sits higher than 78% of all other readings from the past 12 months, suggesting that calls have been preferred over puts during the past 10 weeks.

Grab your FREE Eternal Contrarian report!


Special Offers from Schaeffer's Trading Partners